Vanda Pharmaceuticals (NASDAQ:VNDA) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a strong sell rating in a research report released on Saturday morning.

A number of other brokerages have also commented on VNDA. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.26 on Friday. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $5.55. The firm has a market capitalization of $251.72 million, a price-to-earnings ratio of -3.77 and a beta of 0.72. The business has a 50-day simple moving average of $4.64 and a 200 day simple moving average of $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. On average, sell-side analysts expect that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the transaction, the director owned 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the business’s stock in a transaction on Friday, May 16th. The shares were bought at an average price of $4.22 per share, with a total value of $84,400.00. Following the purchase, the chief executive officer directly owned 2,315,731 shares in the company, valued at approximately $9,772,384.82. The trade was a 0.87% increase in their position. The disclosure for this purchase can be found here. 8.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its stake in shares of Vanda Pharmaceuticals by 2.1% in the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 6,079 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Vanda Pharmaceuticals by 108.9% in the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company’s stock worth $1,608,000 after buying an additional 175,019 shares during the last quarter. Norges Bank purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $551,000. Wellington Management Group LLP boosted its stake in shares of Vanda Pharmaceuticals by 12.7% in the 4th quarter. Wellington Management Group LLP now owns 348,846 shares of the biopharmaceutical company’s stock worth $1,671,000 after buying an additional 39,195 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock worth $6,949,000 after buying an additional 24,483 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.